Abstract:Targeted protein degradation (TPD) technology has gradually become widespread in the past 20 years, which greatly boosts the development of disease treatment. Contrary to small inhibitors that act on protein kinases, transcription factors, ion channels, and other targets they can bind to, targeted protein degraders could target "undruggable targets" and overcome drug resistance through ubiquitin–proteasome pathway (UPP) and lysosome pathway. Nowadays, some bivalent degraders such as proteolysis-targeting chimeras (PROTACs) have aroused great interest in drug discovery, and some of them have successfully advanced into clinical trials. In this review, to better understand the mechanism of degraders, we elucidate the targeted protein degraders according to their action process, relying on the ubiquitin–proteasome system or lysosome pathway. Then, we briefly summarize the study of PROTACs employing different E3 ligases. Subsequently, the effect of protein of interest (POI) ligands, linker, and E3 ligands on PROTAC degradation activity is also discussed in detail. Other novel technologies based on UPP and lysosome pathway have been discussed in this paper such as in-cell click-formed proteolysis-targeting chimeras (CLIPTACs), molecular glues, Antibody-PROTACs (Ab-PROTACs), autophagy-targeting chimeras, and lysosome-targeting chimeras. Based on the introduction of these degradation technologies, we can clearly understand the action process and degradation mechanism of these approaches. From this perspective, it will be convenient to obtain the development status of these drugs, choose appropriate degradation methods to achieve better disease treatment and provide basis for future research and simultaneously distinguish the direction of future research efforts.

Protein degraders push into novel target space

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

[Protein induced proximity and targeted degradations by new degraders: concepts, developments, challenges for clinical applications]

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies

Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders

Bivalent Ligands for Protein Degradation in Drug Discovery

Innovative, combinatorial and high-throughput approaches to degrader synthesis

Targeted protein degradation: expanding the toolbox

Advances in Protein Degradation

Targeted protein degradation: from mechanisms to clinic

Protein degraders enter the clinic — a new approach to cancer therapy

Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic

From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation

[Induced degradation of proteins by PROTACs and other strategies: towards promising drugs]

Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins

Recent advances in targeted protein degraders as potential therapeutic agents

Advancing targeted protein degradation for cancer therapy

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

PROTAC protein degraders to drug the undruggable enter phase 3 trials

The Present and Future of Novel Protein Degradation Technology

Targeted Protein Degradation: The New Frontier of Antimicrobial Discovery?